A Phase II, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (TRIDENT)

Study Identifier:
CORT124134-558
CT.gov Identifier:
NCT07259317
EudraCT Identifier:
N/A
EU Trial (CTIS) Number:
N/A
Study Contact Information:
(210) 593-5651 or [email protected]
Recruiting

Considering participating in a START clinical trial?

Get Started

Study Summary

This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Breast Cancers
Pancreas
Phase
The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
II
Sex
Female & Male
Age
18+ years
Study Drug
Drug: EXPERIMENTAL: Relacorilant in Combination with Nab-paclitaxel and Gemcitabine
Read More
Drug: The patient will receive relacorilant 150 mg, administered orally under fed conditions, once daily for 3 consecutive days on the day before (excluding Cycle 1, day -1), the day of, and the day after nab-paclitaxel and gemcitabine infusions. Nab-paclitaxel (100 mg/m\^2) and gemcitabine (1000 mg/m\^2) will be administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. On days when relacorilant, nab-paclitaxel, and gemcitabine are administered, relacorilant will be administered first, then nab-paclitaxel, and gemcitabine last.
Drug: Drug: Gemcitabine 1000 mg/m^2
Drug: Gemcitabine will be administered via intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle.
Drug: Drug: Nab-paclitaxel 100 mg/m^2
Drug: Nab-paclitaxel will be administered via intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle.
Drug: Drug: Relacorilant 150 mg once daily (QD)
Drug: Relacorilant will be administered as capsules for oral dosing on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel and gemcitabine infusions.
Drug: Other Names: CORT125134
Study Status
Indicates the current recruitment status or the expanded access status
Recruiting

Requirements information
Inclusion criteria
  • * Signed and dated informed consent form prior to screening procedures
  • * Histologic diagnosis or cytologic diagnosis of pancreatic adenocarcinoma (PDAC)
  • * Initial diagnosis of metastatic disease occurred ≤6 weeks prior to enrollment in the study
  • * Life expectancy of ≥3 months
  • * Radiographic confirmation of metastatic disease with at least 1 distant tumor metastasis measurable on radiology imaging per RECIST version 1.1 criteria
  • * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • * Able to provide informed consent and comply with protocol requirements
  • * Able to swallow and retain oral medication and does not have uncontrolled emesis
  • * Has adequate gastrointestinal absorption
  • * Received no prior systemic anticancer therapy to treat metastatic disease
  • * If a patient received prior treatment of PDAC with chemotherapy, disease progression must have occurred >12 months after completing the last dose, and no persistent treatment-related toxicities can be present.
  • * Adequate organ function
  • * Negative pregnancy test for patients of childbearing potential
  • * Agree to use protocol defined precautions to avoid pregnancy
Exclusion criteria
  • Any major surgery within 4 weeks prior to enrollment
  • * Prior treatment as follows:
  • 1. Radiotherapy, surgery, chemotherapy, immunotherapy, investigational therapy for the treatment of metastatic disease
  • 2. Systemic, inhaled, or prescription strength topical corticosteroids within 5 times the half-life of the corticosteroid used prior to first dose of study drug
  • * Received gemcitabine or nab-paclitaxel to treat their PDAC
  • * Known germline or somatic breast cancer gene (BRCA) mutation
  • * Peripheral neuropathy from any cause >Grade 1
  • * Medical conditions requiring chronic or frequent treatment with corticosteroids
  • * History of severe hypersensitivity or severe reaction to any of study drugs or their excipients
  • * Concurrent treatment with mifepristone or other glucocorticoid receptor modulators.
  • * Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
  • * Active infection with HIV, hepatitis C or hepatitis B virus
  • * Known untreated parenchymal brain metastasis or uncontrolled central nervous system metastases
  • * History of other malignancy within 3 years prior to enrollment
  • * Taking protocol-prohibited medications
  • * Concurrent treatment with other investigational treatment studies for cancer
  • * Has received a live vaccine within 30 days prior to the study start date

Clinical Study Information for Healthcare Providers

By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

View Study Information

Study Locations

Location
Investigator
Status
Condition(s) Treated at Site
Location
START Los Angeles
Los Angeles, CA, United States, 90025
Investigator
Lasika Seneviratne
Status
Will Be Recruiting
Condition(s) Treated at Site
Breast Cancers
Pancreas